Skip to main content
    T

    Tempus AI, Inc. Class A Common Stock (TEM)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $64.76
    -6.84 (-9.55%)

    Market Cap: $13.06B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tempus AI, Inc. Class A Common Stock (TEM) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Tempus AI, Inc. Class A Common Stock (TEM) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Tempus AI, Inc. Class A Common Stock reported EPS of -$0.21, above the -$0.32 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(9/10)
    Avg Surprise
    +28.40%
    Streak
    7 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.02
    Range-$0.14 - $0.12
    22 analysts
    Revenue Consensus
    $464.04M
    Range$444.72M - $485.13M
    22 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.11
    Range-$0.27 - $0.00
    11 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.06-93.2%
    60d ago-$0.06-83.1%
    30d ago-$0.06-70.9%
    7d ago-$0.07-49.9%
    Current-$0.11
    Revenue Consensus
    $437.40M
    Range$420.00M - $455.90M
    17 analysts

    Next Report

    TEM has an expected report date of Feb 22, 2027.

    TEM Earnings Call

    The latest TEM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 10 quarters below that had an estimate, TEM beat 9 and missed 1. Revenue for the quarter ended Sep 30, 2026 was $411.54M, up 23.1% from $334.21M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.21-$0.32N/A+34.38%BeatN/A142 up, 1 downNov 2, 2026$411.54M
    Jun 30, 2026-$0.35-$0.41N/A+14.63%BeatN/A125 up, 7 downJul 30, 2026$382.49M
    Mar 31, 2026-$0.13-$0.20-$0.31 - $0.08+35.00%BeatN/A120 up, 1 downMay 5, 2026$348.12M
    Dec 31, 2025-$0.04-$0.20N/A+80.00%BeatN/A111 up, 0 downFeb 24, 2026$367.21M
    Sep 30, 2025-$0.11-$0.18-$0.30 - -$0.08+38.89%BeatN/A85 up, 0 downNov 4, 2025$334.21M
    Jun 30, 2025-$0.22-$0.25-$0.39 - -$0.19+12.00%BeatN/A70 up, 6 downAug 8, 2025$314.63M
    Mar 31, 2025-$0.24-$0.27-$0.38 - -$0.20+11.11%BeatN/A70 up, 2 downMay 6, 2025$255.74M
    Dec 31, 2024-$0.18-$0.15-$0.20 - -$0.06-17.49%MissN/A61 up, 1 downFeb 24, 2025$200.68M
    Sep 30, 2024-$0.25-$0.28-$0.49 - -$0.25+10.71%BeatN/A70 up, 0 downNov 4, 2024$180.93M
    Jun 30, 2024-$0.63-$1.79N/A+64.80%BeatN/AN/AN/AAug 6, 2024$165.97M
    Mar 31, 2024-$0.98N/AN/AN/AN/AN/AN/AN/AJun 17, 2024$145.82M
    Last 11 quarters

    Annual EPS

    Fiscal year endedEPSChange
    Sep 30, 2026-$0.69N/A
    Jun 30, 2026-$0.48N/A
    Dec 31, 2025-$0.61N/A
    Dec 31, 2024-$2.04N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,34313
    2026Q2Jun 30, 20264,74312
    2026Q1Mar 31, 20264,86613
    2025Q4Dec 31, 20254,39615
    2025Q3Sep 30, 20252,26814
    2025Q2Jun 30, 20256,00914
    2025Q1Mar 31, 20255,84313
    2024Q4Dec 31, 20245,85114

    2026Q3 Earnings Call

    Opening remarks

    Elizabeth Krutoholow VP of Investor Relations Thank you, Matt. Good morning, and welcome to Tempus' third quarter 2026 conference call. This morning, Tempus released results for the quarter ended 09/30/2026. The press release, overview of the quarter, and our latest presentation are available on our IR website at investors.tempus.com. Joining me today are Eric Lefkofsky, founder and CEO of Tempus, and Jim Rogers, CFO. Before we begin, I would like to remind you that during this call, management will be making forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to our 10-Ks and other subsequent filings with the SEC. During the call, we will discuss non-GAAP financial measures, which are not prepared in accordance with generally accepted accounting principles. Definitions of these non-GAAP financial measures, along with reconciliations to the most directly comparable GAAP financial measures, are included in our earnings release, which is available on our IR page. We will now turn the call over to Eric.

    Eric Lefkofsky Founder and CEO Q3 was an incredibly strong quarter for Tempus, with broad-based growth across both our diagnostics and data and applications businesses. Momentum from the first half of 2026 carried into the third quarter, with total revenue of $412 million, increasing 23% year over year, led by accelerating unit growth of 32% in our Oncology business and increasing momentum of 33% revenue growth in Data and Apps. Our diagnostics business delivered $304 million of revenue, an increase of 20% year over year, driven by oncology revenues, which grew 28% with volume growth of 32%, as we continue to see some of the strongest unit volume growth we have seen in years. Oncology revenues were $173 million, and hereditary cancer testing revenues were $111 million. Data and Apps revenues were $108 million, increasing 33% year over year, as that business continues to outperform, led by Insights, our data licensing segment, which grew 29%. These results reinforce the durability of our model, as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive the performance we have delivered consistently quarter after quarter. There were also several notable highlights since our last quarterly call. We entered into a strategic collaboration with Bristol Myers Squibb, or BMS, whereby we agreed to license BMS oncology data and models for up to $138 million over a five-year term. Additionally, BMS, Pathos, and Tempus have entered into a collaboration to build datasets and models for Alzheimer's disease. Through this collaboration, Pathos is paying Tempus $55 million over a five-year term.

    Frequently Asked Questions About TEM

    When is Tempus AI, Inc. Class A Common Stock's next earnings date?

    Tempus AI, Inc. Class A Common Stock's next earnings report is expected for Feb 22, 2027.

    Did TEM beat earnings estimates last quarter?

    Yes. Tempus AI, Inc. Class A Common Stock reported EPS of -$0.21 for the quarter ended Sep 30, 2026, above the -$0.32 estimate, a 34.38% surprise.

    What EPS do analysts expect from TEM next quarter?

    The consensus EPS estimate for Tempus AI, Inc. Class A Common Stock for the quarter ending Dec 31, 2026 is -$0.02 from 22 analysts, with estimates from -$0.14 to $0.12.

    How often does TEM beat earnings estimates?

    Tempus AI, Inc. Class A Common Stock beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +26.06%.